

### **AMENDMENTS TO THE CLAIMS**

The following listing of claims will replace all prior versions, and listings, of claims in the application.

1-44. (canceled)

- 45. (new) A composition for treating a pelvic inflammatory condition, comprising a sulfated proteoglycan and at least one ingredient selected from the group consisting of a sulfated hexosamine, a flavonoid, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, a CRH antagonist, caffeine, folic acid, a polyunsaturated fatty acid, and a polyamine.
- 46. (new) The composition of claim 45, wherein the proteoglycan is chondroitin sulfate, keratan sulfate, dermatan sulfate, or sodium hyaluronate.
- 47. (new) The composition of claim 46, wherein the proteoglycan is chondroitin sulfate.
- 48. (new) The composition of claim 45, wherein the flavonoid is quercetin, myricetin, genistein, or rutin.
- 49. (new) The composition of claim 45, further comprising olive kernel extract.
- 50. (new) The composition of claim 49, wherein the olive kernel extract is in the amount of 300-1,200 mg.
- 51. (new) The composition of claim 45, wherein the histamine-1 receptor antagonist is hydroxyzine, merelastine, azelastine, azatadine, or cyproheptadine.
- 52. (new) The composition of claim 47, wherein the sulfated hexosamine is D-glucosamine sulfate.
- 53. (new) The composition of claim 52, wherein the flavonoid is quercetin.
- 54. (new) The composition of claim 45, wherein the proteoglycan is in the amount of 10-3,000 mg, the sulfated hexosamine is in the amount of 10-3,000 mg, and the flavonoid is in the amount of 10-3,000 mg.
- 55. (new) The composition of claim 45, wherein the S-adenosylmethionine is in the amount of 3-1,000 mg.

56. (new) The composition of claim 45, wherein the proteoglycan is chondroitin sulfate, the flavonoid is quercetin, and the histamine-1 receptor antagonist is hydroxyzine.
57. (new) The composition of claim 56, wherein the chondroitin sulfate is in the amount of 50-300 mg, the quercetin is in the amount of 50-300 mg, and the hydroxyzine is in the amount of 50-300 mg.
58. (new) The composition of claim 45, wherein the proteoglycan is chondroitin sulfate, the flavonoid is myricetin, and the histamine-1 receptor antagonist is hydroxyzine.
59. (new) The composition of claim 58, wherein the chondroitin sulfate is in the amount of 50-300 mg, the myricetin is in the amount of 50-300 mg, and the hydroxyzine is in the amount of 50-300 mg.
60. (new) A method of treating a pelvic inflammatory condition, comprising administering an effective amount of the composition of claim 45 to a subject in need thereof.
61. (new) A method of treating a pelvic inflammatory condition, comprising administering an effective amount of the composition of claim 53 to a subject in need thereof.
62. (new) A method of treating a pelvic inflammatory condition, comprising administering an effective amount of the composition of claim 56 to a subject in need thereof.
63. (new) A method of treating a pelvic inflammatory condition, comprising administering an effective amount of the composition of claim 58 to a subject in need thereof.